Cardiac safety assays

11
Mar

New Partnership for Comprehensive In Vitro Cardiac Safety Assessment

PhysioStim & ACEA Biosciences announce partnershipA hi-tech alliance to measure preclinical cardiac safety in vitroACEA Biosciences and PhysioStim will work together to provide comprehensive in vitro cardiac safety and toxicity assessment services for pharmaceutical and biotechnology companies in Europe.Press release ACEA Biosciences Inc. (ACEA), now a part of Agilent Technologies, is a pioneer in the development and commercialization of high
Read more
13
Feb

A new model to study chronotropic effects

PhysioStim adds new model to study chronotropic effectsTo check the cardiac safety of new drugs and compounds, PhysioStim has now added a new study model to detect potential chronotropic effects.What are chronotropic effects? Drugs and compounds with chronotropic effects change the heart rate and rhythm by affecting the electrical conduction system of the heart and the nerves that influence it.
Read more
6
Dec

Safety pharmacology studies using human cardiomyocytes

Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) hold great potential for safety pharmacology studies. Human iPSC-derived cardiomyocytes can be used for high throughput screening, MEA, patch clamp and disease modeling applications.

21
Sep

Preclinical cardiovascular electrophysiology

Creating a European Centre of Excellence dedicated to Cardiac Safety Evaluation

13
Sep

cardiovascular safety studies

The company has received international recognition for its expertise in cardiac electrophysiology and preclinical safety studies. To expand its reach and complete its range of services and assays, PhysioStim is expected to team up with another CRO from across the Channel.